Nexalin Gen-2 neurostimulation device approved by Brazilian regulator Anvisa

Nexalin Technology, Inc.

Anvisa approved Nexalin's Gen-2 15 mA neurostimulation device for sale in Brazil.
This is Nexalin's second regulatory approval outside China in 2024.
Brazil has >215M population, >35M with mental health disorders; 9th largest economy.
CEO says approval is springboard into other South American markets; distributor talks underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.